capsule molle
Sponsors
Institut Gustave Roussy, Institut Gustave Roussy, Amolyt Pharma, Assistance Publique Hopitaux De Paris, Centre Hospitalier Universitaire De Nice, Assistance Publique Hopitaux De Marseille
Conditions
AcneChildren and teenagers with refractory/relapsing solid tumorEpendymomaHypoparathyroidismMedulloblastomaOligometastatic solid cancerPrimary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)pediatric cancer
Phase 1
Pan-lesions SBRT combined with lymphocyte support through ATRA-driven blockade of MDSC in patients with oligometastatic solid cancer (LySATRA)
RecruitingCTIS2022-500680-13-00
Start: 2024-07-04Target: 58Updated: 2025-03-18
Phase 1 study of a Propranolol (HEMANGIOL®) and oral metronomic Vinorelbine (NAVELBINE®) combination on children and teenagers With Refractory/Relapsing Solid Tumors - PROVIN
RecruitingCTIS2024-517185-42-00
Start: 2020-05-04Target: 58Updated: 2025-09-09
MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medulloblastoma and ependymoma
RecruitingCTIS2023-509585-38-00
Start: 2024-11-19Target: 40Updated: 2025-11-07
AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
RecruitingCTIS2024-514791-40-00
Start: 2016-08-03Target: 398Updated: 2025-10-06
Phase 3
A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)
WithdrawnCTIS2022-503126-12-00
Target: 12Updated: 2023-07-25
A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)
RecruitingCTIS2022-503126-12-01
Start: 2024-01-05Target: 112Updated: 2025-07-28
Randomized clinical trial to compare oral isotretinoin to standard of care in moderate acne skin of color patients
RecruitingCTIS2023-507519-36-00
Start: 2025-04-29Target: 420Updated: 2025-12-15
CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia
Not yet recruitingCTIS2023-507010-27-00
Target: 70Updated: 2026-03-05